Life sciences

Straightforward business-friendly advice from lawyers who understand the unique challenges and opportunities presented by the life sciences sector.  We enjoy spending time getting to know our clients and working alongside them for the long term.
  • Profile
  • Experience
  • Key contacts

We work with a wide range of clients from the life sciences sector including:

  • pharmaceutical companies
  • biotechnology companies
  • medical device and diagnostic companies
  • manufacturers, distributors and logistics companies
  • investors
  • banks and financial institutions.

We work with companies of all sizes, from start-ups to multinational industry leaders. Whether it's a complex matter affecting your entire business or a more routine matter, we have the knowledge and commitment to assist you.

We have particular expertise in:

  • acquisitions and disposals
  • investments and financings
  • IPOs
  • licensing deals
  • collaboration agreements
  • manufacturing, distribution and logistics contracts
  • multi-jurisdictional disputes
  • intellectual property
  • tax structuring
  • competition/anti-trust issues
  • employment, pensions and incentives advice
  • data privacy issues
  • real estate for laboratory and manufacturing facilities, including associated planning and environmental matters.
"High-quality advice, personable solicitors, great individual care and attention. A team who genuinely care and want to make a different to their clients whether to win, negotiate or settle."
The Legal 500 UK 2020

Woodford Investment Management

We advised on the set up and launch of Woodford Patient Capital Trust plc, an innovative investment trust offering exposure to early-stage companies with outstanding intellectual property and long-term return opportunities.

Vernalis plc

We have advised this AIM-listed development stage pharmaceutical company on a number of out-licensing and collaboration deals, including the out-licensing of the worldwide rights to its proprietary adenosine receptor antagonist technology to a US company.


We have advised GSK on a number of trade mark matters including a multi-jurisdictional dispute relating to the colour of its global blockbuster inhaler product, Seretide.

BTG plc

We have advised BTG plc, a FTSE-250 international specialist pharmaceutical company, on a range of M&A, financing and licensing matters including its $220 million acquisition of EKOS Corporation, an International vascular business, headquartered in Seattle, US.

ARIAD Pharmaceuticals

We have assisted this specialist oncology company, headquartered in Cambridge (Massachusetts), with commercial, competition, data protection and employment advice related to its entry into the European market.


We have advised this global biopharma company on a variety of significant and more routine commercial contracts and a dispute with a licensing partner.

Piramal Enterprises

We have advised this Mumbai-listed company on a wide variety of matters, including the sale of its domestic formulations division to Abbot Healthcare for $3.8 billion.

Lansen Pharmaceutical Holdings Limited

We advised Lansen on its acquisition from Novartis AG of the rights to sell Sicorten Plus, a dermatological product, in China.

Eisai Europe Ltd

We have advised this Japanese headquartered pharmaceutical company on confidential employment and HR matters in the UK for many years.


We have advised this Global 500 company on corporate governance, data protection, competition law compliance, and medical advertising in Asia.


Giovanna Kwong Partner

T:  +852 2533 2787
M:  Email Giovanna | Vcard Office:  Hong Kong


Alexandra Pygall Partner

T:  +44 20 7809 2137
M:  +44 7881 314 566 Email Alexandra | Vcard Office:  London

Latest news & insights

04 Sep 2020

From News

Stephenson Harwood advises Oxford Biomedica on further Covid-19 vaccine deal

Law firm Stephenson Harwood LLP has advised gene and cell therapy company Oxford Biomedica on a second supply agreement with AstraZeneca, to expand the manufacturing s..


13 Jul 2020

From Insights

COVID-19 considerations for life sciences M&A

This note sets out some COVID-19 considerations for M&A which are specific to the life sciences sector.


08 Jul 2020

From News

Stephenson Harwood advises e-therapeutics plc on fundraise of up to £12.4 million

Law firm Stephenson Harwood LLP has advised e-therapeutics plc on fundraise of up to £12.4 million.


01 Jun 2020

From News

Stephenson Harwood advises Oxford Biomedica on COVID-19 vaccine with AstraZeneca

Law firm Stephenson Harwood LLP has advised Oxford Biomedica plc (Oxford Biomedica), a gene and cell therapy company, on a Clinical and Commercial Supply Agreement wit..


18 May 2020

From Insights

How to practise safe working in labs and research facilities

To help these employers meet their legal and moral responsibility to protect employees from risk to their health and safety, we have distilled the Government's guidanc..


07 May 2020

From Insights

Antitrust: Impact of COVID-19 on life sciences

We look at the likely impact of the COVID-19 pandemic on competition law in the life sciences sector.


24 Mar 2020

From Insights

Biotech listings in Hong Kong

Biotech and life sciences


19 Mar 2020

From News

Stephenson Harwood advises Oxford Biomedica on gene therapy deal with Juno Therapeutics

Law firm Stephenson Harwood LLP has advised Oxford Biomedica plc (Oxford Biomedica), a gene and cell therapy company, on a Licence and Clinical Supply Agreement (LSA) ..


28 Jan 2020

From Insights

Documents disclosed to the EMA as part of an MA application process are not presumed to be confidential

On 22 January 2020 the CJEU handed down two decisions in which it decided that the EMA was entitled to disclose to third parties the study reports submitted to it by a..


09 Dec 2019

From News

Stephenson Harwood advises capiton on KD Pharma single-asset secondary

Law firm Stephenson Harwood LLP has advised private equity firm capiton on a general partner-led single asset secondary transaction relating to the KD Pharma Group.


© Stephenson Harwood LLP 2016. Any reference to Stephenson Harwood in this document means Stephenson Harwood LLP and/or its affiliated undertakings. Any reference to a partner is used to refer to a member of Stephenson Harwood LLP.